Literature DB >> 9846574

Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells.

J Desbarats1, R C Duke, M K Newell.   

Abstract

Fas Ligand (FasL) can induce apoptosis of Fas-bearing cells. It is expressed on the cell surface of many tumor cells, immune-privileged tissues and activated lymphocytes. We report here that FasL can itself transduce signals, leading to cell-cycle arrest and cell death in CD4+ T cells. In vitro, FasL engagement inhibited CD4+ T-cell proliferation, cell-cycle progression, and IL-2 secretion. In vivo, FasL engagement prevented superantigen-mediated CD4+, but not CD8+, T-cell expansion. These findings demonstrate that FasL engagement regulates cell-cycle progression, and show that FasL engagement in vivo has a potent anti-inflammatory effect specific for CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846574     DOI: 10.1038/3965

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  22 in total

Review 1.  Apoptosis.

Authors:  S Afford; S Randhawa
Journal:  Mol Pathol       Date:  2000-04

2.  Stimulation of FasL induces production of proinflammatory mediators through activation of mitogen-activated protein kinases and nuclear factor-κB in THP-1 cells.

Authors:  Sang-Min Lee; Eun-Ju Kim; Kyoungho Suk; Won-Ha Lee
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

3.  Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.

Authors:  Thomas Kolben; Udo Jeschke; Toralf Reimer; Nora Karsten; Elisa Schmoeckel; Anna Semmlinger; Sven Mahner; Nadia Harbeck; Theresa M Kolben
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-28       Impact factor: 4.553

4.  Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.

Authors:  Jie-Hui Li; Dalia Rosen; Paul Sondel; Gideon Berke
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

5.  Crucial Fas-Fas ligand interaction in spontaneous acceptance of hepatic allografts in mice.

Authors:  Hideaki Uchiyama; Kenji Kishihara; Ryosuke Minagawa; Koji Hashimoto; Keizo Sugimachi; Kikuo Nomoto
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

Review 6.  The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.

Authors:  Frédéric Rieux-Laucat; Aude Magérus-Chatinet; Bénédicte Neven
Journal:  J Clin Immunol       Date:  2018-06-17       Impact factor: 8.317

7.  Inhibition of Fas-Fas ligand interaction attenuates microvascular hyperpermeability following hemorrhagic shock.

Authors:  Devendra A Sawant; Binu Tharakan; Richard P Tobin; Hayden W Stagg; Felicia A Hunter; M Karen Newell; W Roy Smythe; Ed W Childs
Journal:  Shock       Date:  2013-02       Impact factor: 3.454

8.  The distribution and intracellular location of Fas and Fas Ligand following gastric carcinogenesis: Fas Ligand expressing gastric carcinoma cells can inhibit local immune response.

Authors:  Huanran Liu; Hideyuki Ubukata; Takanobu Tabuchi; Takeshi Nakachi; Hiroyuki Nagata; Jiro Shimazaki; Gyou Motohashi; Satoru Konishi; Motoi Nishimura; Tetsuro Satani; JianWei Hong; Ichiro Nakada; Abbi R Saniabadi; Takafumi Tabuchi
Journal:  Mol Cell Biochem       Date:  2009-05-21       Impact factor: 3.396

9.  Status of autoimmune diabetes 20-year after generation of BDC2.5-TCR transgenic non-obese diabetic mouse.

Authors:  Lourdes Ramirez; Abdel Rahim A Hamad
Journal:  World J Diabetes       Date:  2013-08-15

10.  Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically.

Authors:  Abdiaziz S Mohamood; Mehmet L Guler; Zuoxiang Xiao; Dongfeng Zheng; Allan Hess; Yi Wang; Hideo Yagita; Jonathan P Schneck; Abdel Rahim A Hamad
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.